Kymera Therapeutics, Inc.

NasdaqGM:KYMR Stock Report

Market Cap: US$7.1b

Kymera Therapeutics Valuation

Is KYMR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of KYMR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate KYMR's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate KYMR's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KYMR?

Key metric: As KYMR barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for KYMR. This is calculated by dividing KYMR's market cap by their current book value.
What is KYMR's PB Ratio?
PB Ratio4.4x
BookUS$1.58b
Market CapUS$7.13b

Price to Book Ratio vs Peers

How does KYMR's PB Ratio compare to its peers?

The above table shows the PB ratio for KYMR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average6.9x
APGE Apogee Therapeutics
7x0.32%US$6.4b
NUVL Nuvalent
6.5x55.19%US$8.2b
PCVX Vaxcyte
3.3x39.30%US$8.9b
COGT Cogent Biosciences
10.7x61.08%US$6.0b
KYMR Kymera Therapeutics
4.4x-3.46%US$7.1b

Price-To-Book vs Peers: KYMR is good value based on its Price-To-Book Ratio (4.4x) compared to the peer average (6.9x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does KYMR's PB Ratio compare vs other companies in the US Biotechs Industry?

58 CompaniesPrice / BookEstimated GrowthMarket Cap
ENLV Enlivex
0.1x-74.01%US$225.42m
CNTN Canton Strategic Holdings
0.4xn/aUS$192.63m
NKTX Nkarta
0.5x-3.03%US$166.82m
ACET Adicet Bio
0.5x26.03%US$73.74m
KYMR 4.4xIndustry Avg. 2.3xNo. of Companies83PB0246810+
58 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: KYMR is expensive based on its Price-To-Book Ratio (4.4x) compared to the US Biotechs industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is KYMR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KYMR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate KYMR's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst KYMR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$85.05
US$119.14
+40.09%
9.58%US$140.00US$91.00n/a21
Apr ’27US$84.93
US$119.14
+40.28%
9.58%US$140.00US$91.00n/a21
Mar ’27US$91.35
US$118.00
+29.17%
10.74%US$140.00US$90.00n/a21
Feb ’27US$72.69
US$116.71
+60.56%
11.05%US$138.00US$90.00n/a21
Jan ’27US$77.81
US$115.64
+48.61%
10.73%US$138.00US$90.00n/a22
Dec ’26US$66.86
US$77.59
+16.05%
12.11%US$98.00US$65.00n/a22
Nov ’26US$61.84
US$69.05
+11.65%
12.36%US$92.00US$53.00n/a22
Oct ’26US$54.66
US$64.33
+17.70%
12.30%US$92.00US$53.00n/a21
Sep ’26US$41.20
US$60.37
+46.53%
8.96%US$70.00US$53.00n/a19
Aug ’26US$42.96
US$60.26
+40.28%
8.96%US$70.00US$53.00n/a19
Jul ’26US$44.44
US$61.00
+37.26%
11.11%US$79.00US$53.00n/a19
Jun ’26US$29.64
US$56.68
+91.24%
20.17%US$97.00US$38.00n/a19
May ’26US$34.55
US$57.67
+66.91%
19.90%US$97.00US$41.00n/a18
Apr ’26US$25.24
US$57.95
+129.63%
19.58%US$97.00US$41.00US$84.9319
Mar ’26US$31.35
US$58.11
+85.34%
19.41%US$97.00US$41.00US$91.3519
Feb ’26US$39.59
US$58.84
+48.63%
18.66%US$97.00US$41.00US$72.6919
Jan ’26US$40.23
US$58.74
+46.00%
16.76%US$90.00US$41.00US$77.8119
Dec ’25US$46.85
US$57.76
+23.30%
19.86%US$90.00US$38.00US$66.8617
Nov ’25US$46.47
US$57.56
+23.87%
21.98%US$90.00US$38.00US$61.8416
Oct ’25US$46.57
US$55.88
+19.98%
30.15%US$106.00US$36.00US$54.6616
Sep ’25US$48.36
US$53.69
+11.02%
32.82%US$106.00US$33.00US$41.2016
Aug ’25US$44.49
US$51.13
+14.93%
39.38%US$112.00US$30.00US$42.9615
Jul ’25US$30.95
US$50.80
+64.14%
40.20%US$112.00US$30.00US$44.4415
Jun ’25US$32.11
US$50.80
+58.21%
40.20%US$112.00US$30.00US$29.6415
May ’25US$36.24
US$51.07
+40.91%
39.87%US$112.00US$30.00US$34.5515
Apr ’25US$39.42
US$50.93
+29.19%
41.37%US$112.00US$30.00US$25.2414
US$119.14
Fair Value
28.6% undervalued intrinsic discount
21
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/10 13:48
End of Day Share Price 2026/04/10 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kymera Therapeutics, Inc. is covered by 37 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Eliana MerleBarclays
Zhiqiang ShuBerenberg